Company
Ann Arbor, OS
Every investor coverage indicates participated in a round University of Michigan raised.
Companies University of Michigan acquired or merged with, per published coverage. Buying a company is not investing in one: nothing here counts in the deals column.
| Name | Role | Sources |
|---|---|---|
| Professor Dinesh Khanna | Frederick G.L. Huetwell Professor of Rheumatology and Director, Scleroderma Program | Brandon Capital, Brandon BioCatalyst |
Stories naming University of Michigan. Where several outlets covered the same round, they are bundled under whichever ran the fullest account.
A year-end list profiling women leaders worldwide, from presidents to tech founders; it recalls Airwallex's landmark capital raise and Mira Murati's new AI venture with its record seed round.
Also Forbes Australia
Melbourne biotech Certa Therapeutics reported encouraging Phase 2 results for its scleroderma drug FT011 at a US rheumatology meeting, with safety confirmed and a pivotal trial planned.
Australian biotech Certa Therapeutics reports Phase 2 scleroderma trial results for FT011 at a US rheumatology meeting, showing efficacy and safety, with a pivotal study planned.